IRLAB Therapeutics AB OMXSTO:IRLAB_A:
SAID ON MONDAY ANNOUNCES OUTCOME OF RIGHTS ISSUE
RIGHTS ISSUE WILL PROVIDE COMPANY WITH PROCEEDS OF ABOUT SEK 68 MILLION BEFORE DEDUCTION OF COSTS RELATED TO RIGHTS ISSUE
RIGHTS ISSUE IS SUBSCRIBED TO ABOUT 112.6% WITH AND WITHOUT SUPPORT OF SUBSCRIPTION RIGHTS
OVERALLOTMENT ISSUE WILL PROVIDE COMPANY WITH ADDITIONAL PROCEEDS OF ABOUT SEK 8.6 MILLION BEFORE DEDUCTION OF ISSUE COSTS
Source text:
Further company coverage: [IRLABa.ST]